Alzamend Neuro (ALZN) Interest Coverage Ratio (QoQ) (2020 - 2026)
Powered by 
Analysis
Alzamend Neuro (ALZN) Interest Coverage Ratio (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.68 Bn | 193.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.05 Bn | 123.20 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.80 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.99 Bn | 55.81 Bn | 1.37 Bn |
| 6 | Moderna | 53.41 Bn | 48.27 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.72 Bn | 30.43 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.53 Bn | 29.53 Bn | 1.16 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -1,064.38% |
| Jan 31, 2026 | -336.25% |
| Oct 31, 2025 | 65.35% |
| Jul 31, 2025 | 51.40% |
| Apr 30, 2025 | -335.48% |
| Jan 31, 2025 | -32.23% |
| Oct 31, 2024 | -384.75% |
| Jul 31, 2024 | 86.19% |
| Apr 30, 2024 | 45.73% |
| Jan 31, 2024 | -58.83% |
| Oct 31, 2023 | 64.97% |
| Jul 31, 2023 | 69.83% |
| Apr 30, 2023 | -142.11% |
| Jan 31, 2023 | -203.80% |
| Oct 31, 2022 | 56.31% |
| Jul 31, 2022 | 69.20% |
| Apr 30, 2022 | -4,001.40% |
| Jan 31, 2022 | 30.00% |
| Oct 31, 2021 | -32.40% |
| Jul 31, 2021 | -374.96% |